Literature DB >> 9383577

Therapeutic applications of catalytic antisense RNAs (ribozymes).

J J Rossi1.   

Abstract

Ribozymes have progressed from an intriguing subject of scientific study to therapeutic agents for the potential treatment of a fatal and devastating viral infection. Despite this rapid road to clinical trials, there are many unexplored avenues that should be examined to improve the intracellular effectiveness of ribozymes. Since ribozymes are RNA molecules, the cellular rules governing RNA partitioning and stability can be applied to these molecules to make them more effective therapeutic agents. Future, successful therapeutic ribozyme applications will depend upon increasing our knowledge of RNA metabolism and movement, and applying this knowledge to the design of ribozymes. This chapter discusses experimental approaches towards this goal as well as recent progress in the application of a pair of hammerhead ribozymes for the clinical treatment of HIV1 infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9383577     DOI: 10.1002/9780470515396.ch14

Source DB:  PubMed          Journal:  Ciba Found Symp        ISSN: 0300-5208


  5 in total

1.  Rapid kinetic characterization of hammerhead ribozymes by real-time monitoring of fluorescence resonance energy transfer (FRET).

Authors:  K K Singh; R Parwaresch; G Krupp
Journal:  RNA       Date:  1999-10       Impact factor: 4.942

2.  Ribozyme rescue of photoreceptor cells in P23H transgenic rats: long-term survival and late-stage therapy.

Authors:  M M LaVail; D Yasumura; M T Matthes; K A Drenser; J G Flannery; A S Lewin; W W Hauswirth
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

3.  New modalities in oncology: ribozymes.

Authors:  C Casey Cunningham
Journal:  Proc (Bayl Univ Med Cent)       Date:  2002-07

4.  Intracellular ribozyme-catalyzed trans-cleavage of RNA monitored by fluorescence resonance energy transfer.

Authors:  D Vitiello; D B Pecchia; J M Burke
Journal:  RNA       Date:  2000-04       Impact factor: 4.942

5.  Down-regulation of the M6P/IGF-II receptor increases cell proliferation and reduces apoptosis in neonatal rat cardiac myocytes.

Authors:  Zhihong Chen; Yinlin Ge; Jing X Kang
Journal:  BMC Cell Biol       Date:  2004-04-28       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.